These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25730094)

  • 1. The future of comparative effectiveness and relative efficacy of drugs: an international perspective.
    Messner DA; Towse A; Mohr P; Garau M
    J Comp Eff Res; 2015 Aug; 4(4):419-27. PubMed ID: 25730094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020.
    Messner DA; Mohr P; Towse A
    J Comp Eff Res; 2015 Aug; 4(4):385-400. PubMed ID: 25730709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020.
    Towse A; Garau M; Mohr P; Messner DA
    J Comp Eff Res; 2015 Aug; 4(4):401-18. PubMed ID: 25740283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
    Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using health technology assessment to identify gaps in evidence and inform study design for comparative effectiveness research.
    Tunis SR; Turkelson C
    J Clin Oncol; 2012 Dec; 30(34):4256-61. PubMed ID: 23071248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies.
    Falissard B; Izard V; Xerri B; Bouvenot G; Meyer F; Degos L
    Int J Technol Assess Health Care; 2010 Jan; 26(1):124-30. PubMed ID: 20059790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness research in radiation oncology: assessing technology.
    Chen AB
    Semin Radiat Oncol; 2014 Jan; 24(1):25-34. PubMed ID: 24314339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priority setting for health in emerging markets.
    Glassman A; Giedion U; McQueston K
    J Comp Eff Res; 2013 May; 2(3):283-91. PubMed ID: 24236627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating new approaches for clinical development: translational research and relative effectiveness.
    Lehner JP; Epstein RS; Salimi T
    J Comp Eff Res; 2012 Jan; 1(1 Suppl):15-21. PubMed ID: 24237318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing CER: what will it take?
    Biskupiak JE; Dunn JD; Holtorf AP
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S19-29. PubMed ID: 22663296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH.
    Puig-Peiro R; Mason A; Mestre-Ferrandiz J; Towse A; McGrath C; Jonsson B
    Int J Technol Assess Health Care; 2015; 31(6):371-9. PubMed ID: 26788883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries.
    Levy AR; Garrison LP
    Value Health; 2010 Jun; 13 Suppl 1():S1-3. PubMed ID: 20618787
    [No Abstract]   [Full Text] [Related]  

  • 16. [Health Technology Assessment: conceptual framework and international perspective].
    Kuhn-Barrientos L
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S11-5. PubMed ID: 24861174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices.
    Husereau D; Henshall C; Jivraj J
    Int J Technol Assess Health Care; 2014 Jul; 30(3):241-9. PubMed ID: 24921416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.
    Gibson SG; Lemmens T
    Med Law Rev; 2014; 22(2):200-20. PubMed ID: 24841527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
    Haas M; Hall J; Viney R; Gallego G
    Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment: a review of international activity and examples of approaches with computed tomographic colonography.
    Husereau D; Morrison A; Battista R; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):343-52. PubMed ID: 19394575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.